Scottish HTA Requests More Data For Orphan Drugs
Executive Summary
The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.
You may also be interested in...
Better Discount To Bylvay £255,000 List Price Sways England’s NICE
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
New Sickle Cell Treatment & Ten Other Drugs Win English Funding Approval
Health technology assessment body NICE has also issued guidances rejecting three products.
UK Government Reveals New Statutory Pricing Scheme
The scheme still includes high rebate rates, but a controversial life cycle adjustment mechanism has been dropped.